2026 Global Angioedema Leadership Conference
Mar 27 - Mar 28, 2026
- Title: Results of the Phase 3 RAPIDe-3 Study of Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks
Presenter: Danny M. Cohn, M.D., Ph.D.
Format: Poster, #57
Date, time: Friday, March 27, 6:10 p.m. CET (1:00 p.m. ET) - Title: End of Progression of Hereditary Angioedema Attacks with Oral Deucrictibant Immediate-Release Capsule: RAPIDe-3 Phase 3 Trial
Presenter: Marc A. Riedl, M.D., M.S.
Format: Poster with presentation, #29
Date, time: Friday, March 27, 6:10 p.m. CET (1:00 p.m.ET) - Title: CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema
Presenter: Andrea Zanichelli, M.D., Ph.D.
Format: Poster with presentation, #61
Date, time: Friday, March 27, 6:10 p.m. CET (1:00 p.m.ET) - Title: Lived Patient Experiences of Hereditary Angioedema Based on Attacks and Associated Symptoms: An Innovative Conceptual Model
Presenter: Raffi Tachdjian, M.D., MPH.
Format: Poster, #16
Date, time: Friday, March 27, 6:10 p.m. CET (1:00 p.m.ET) - Title: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema
Presenter: Emel Aygören-Pürsün, M.D.
Format: Oral presentation with poster, #12
Date, time: Friday, March 28, 9:40 a.m. CET (4:40 a.m.ET)